These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24858652)

  • 1. Acquired echinocandin resistance in a Candida krusei blood isolate confirmed by mutations in the fks1 gene.
    Prigitano A; Esposito MC; Cogliati M; Pitzurra L; Santamaria C; Tortorano AM
    New Microbiol; 2014 Apr; 37(2):237-40. PubMed ID: 24858652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of L701 M mutation in the FKS1 gene of echinocandin-susceptible Candida krusei isolates.
    Lallitto F; Prigitano A; Mangione F; Piralla A; Tamarozzi F; Marone P; Cavanna C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):311-314. PubMed ID: 30131237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
    Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
    J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
    Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
    Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.
    Kahn JN; Garcia-Effron G; Hsu MJ; Park S; Marr KA; Perlin DS
    Antimicrob Agents Chemother; 2007 May; 51(5):1876-8. PubMed ID: 17325225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.
    Jensen RH; Justesen US; Rewes A; Perlin DS; Arendrup MC
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3550-2. PubMed ID: 24687511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
    Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
    Cleary JD; Garcia-Effron G; Chapman SW; Perlin DS
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2263-5. PubMed ID: 18378714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
    Hakki M; Staab JF; Marr KA
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2522-4. PubMed ID: 16801435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
    Espinel-Ingroff A; Cantón E
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():3-9. PubMed ID: 21420570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.
    Forastiero A; Garcia-Gil V; Rivero-Menendez O; Garcia-Rubio R; Monteiro MC; Alastruey-Izquierdo A; Jordan R; Agorio I; Mellado E
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6975-82. PubMed ID: 26324281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel
    Hou X; Healey KR; Shor E; Kordalewska M; Ortigosa CJ; Paderu P; Xiao M; Wang H; Zhao Y; Lin LY; Zhang YH; Li YZ; Xu YC; Perlin DS; Zhao Y
    Emerg Microbes Infect; 2019; 8(1):1619-1625. PubMed ID: 31711370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance.
    Chowdhary A; Prakash A; Sharma C; Kordalewska M; Kumar A; Sarma S; Tarai B; Singh A; Upadhyaya G; Upadhyay S; Yadav P; Singh PK; Khillan V; Sachdeva N; Perlin DS; Meis JF
    J Antimicrob Chemother; 2018 Apr; 73(4):891-899. PubMed ID: 29325167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot mutations on Candida albicans fitness and virulence.
    Ben-Ami R; Kontoyiannis DP
    Virulence; 2012; 3(1):95-7. PubMed ID: 22286697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated chitin content reduces the susceptibility of Candida species to caspofungin.
    Walker LA; Gow NA; Munro CA
    Antimicrob Agents Chemother; 2013 Jan; 57(1):146-54. PubMed ID: 23089748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.
    Fekkar A; Meyer I; Brossas JY; Dannaoui E; Palous M; Uzunov M; Nguyen S; Leblond V; Mazier D; Datry A
    Antimicrob Agents Chemother; 2013 May; 57(5):2380-2. PubMed ID: 23439642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal resistance does not necessarily affect Candida glabrata fitness.
    Borghi E; Andreoni S; Cirasola D; Ricucci V; Sciota R; Morace G
    J Chemother; 2014 Feb; 26(1):32-6. PubMed ID: 24091025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong
    Schell WA; Jones AM; Garvey EP; Hoekstra WJ; Schotzinger RJ; Alexander BD
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.